“We can no longer look at this disease as one in which we should always be measuring survival in months,” said UCLA’s Dr. Edward Garon, the lead author.
When psychiatric medications are abruptly discontinued, withdrawal symptoms may be mistaken for relapse
UCLA research contributes to assessing the reliability of industry-funded drug trials.
Class of 2019 medical students across the country learned which hospital has accepted them for residency, or advanced training in their chosen specialty.
A preview of the paper that was posted on the website ChemRxiv was downloaded 19,000 times in 24 hours, shattering the site’s previous record of 15,000 downloads in six months.
The study suggests that using pembrolizumab and SD-101 together could be effective for people whose tumors have not responded to other therapies.
Chemical engineer Yunfeng Lu has helped develop a way to deliver natural enzymes to the liver, speeding up the metabolism of alcohol.
Housed inside the California NanoSystems Institute, Magnify helps startups succeed by providing access to equipment and entrepreneurial networking.
Class of 2018 medical students across the country learned which hospital has accepted them for residency, or advanced training in their chosen specialty.
UCLA chemistry professor helped develop Erleada, which was recently approved by the FDA for treating an especially lethal form of prostate cancer.
Device that measures cell strength could help identify drugs for asthma, hypertension and muscular dystrophy
“This technology is a game-changer for us drug discovery scientists,” said Robert Damoiseaux, a UCLA professor of molecular and medical pharmacology.
UCLA scientists used leading-edge genomics to identify and eliminate the virus’ defense mechanisms, enabling them to develop a vaccine “candidate” that is safe and effective in animals.
UCLA professor of social welfare co-authored new report showing that more than half of people succeed in discontinuing usage of psychiatric medications.
A team of UCLA scientists is testing an experimental drug that could one day result in a treatment for osteoporosis, which affects more than 200 million people worldwide.
Test developed by UCLA researchers would help physicians determine which people may be more treatable with an antibiotic that has not been recommended since 2007.
The findings lay the groundwork for developing new and improved combination therapies for patients who resistant to stand-alone immunotherapy.
Dr. Richard Finn led the clinical studies that led to the approval of regorafenib, which is used to treat hepatocellular carcinoma.
Dr. Kelsey Martin, who recently was elected to the National Academy of Medicine, is the first woman dean of UCLA’s medical school, and she is among only a handful of women leading a medical school in the United States.
This year, St. Patrick's Day coincided with Match Day, the day when 40,000 aspiring doctors nationwide find out simultaneously which hospitals have accepted them for 30,000 residency slots across the United States.
Dr. David Talan is on a research team that's studying whether treating appendicitis solely with antibiotics can be a safe, effective and less expensive alternative to surgery.
UCLA School of Nursing researchers found that people with a certain genetic variation who took donepezil for the condition had a faster cognitive decline than those who took a placebo.
Dr. Ippolytos Kalofonos has woven together his interests in global health, medicine and culture into a career as a medical anthropologist.
UCLA psychiatrist Dr. Larissa Mooney explains in this Q&A how allowing pharmacies to dispense naloxone leads to a reduction in overdoses.
UCLA researchers determined for the first time why some people with advanced melanoma or advanced colon cancer will not respond to pembrolizumab.
The study is the first to evaluate the medication as a possible treatment for alcoholism.
A UCLA-led research team has identified a drug and dose regimen that may cut the time by as much as 75 percent, while simultaneously reducing the risk that patients could develop drug-resistant TB.